|
2024 Journal Article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialBührer, Emanuel, Kicinski, Michal, Mandala, Mario, Pe, Madeline, Long, Georgina V, Atkinson, Victoria, Blank, Christian U, Haydon, Andrew, Dalle, Stéphane, Khattak, Adnan, Carlino, Matteo S, Meshcheryakov, Andrey, Sandhu, Shahneen, Puig, Susana, Schadendorf, Dirk, Jamal, Rahima, Rutkowski, Piotr, van den Eertwegh, Alfonsus J M, Coens, Corneel, Grebennik, Dmitri, Krepler, Clemens, Robert, Caroline and Eggermont, Alexander M M (2024). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 25 (9), 1202-1212. doi: 10.1016/S1470-2045(24)00338-3 |
|
2024 Journal Article Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in CheckMate 238Weber, Jeffrey, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Maria, De La Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A. and Larkin, James (2024). Outcomes with postrecurrence systemic therapy following adjuvant checkpoint inhibitor treatment for resected melanoma in CheckMate 238. Journal of Clinical Oncology. doi: 10.1200/JCO.23.01448 |
|
2024 Journal Article Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III MelanomaBlank, Christian U., Lucas, Minke W., Scolyer, Richard A., van de Wiel, Bart A., Menzies, Alexander M., Lopez-Yurda, Marta, Hoeijmakers, Lotte L., Saw, Robyn P. M., Lijnsvelt, Judith M., Maher, Nigel G., Pulleman, Saskia M., Gonzalez, Maria, Acosta, Alejandro Torres, van Houdt, Winan J., Lo, Serigne N., Kuijpers, Anke M. J., Spillane, Andrew, Klop, W. Martin C., Pennington, Thomas E., Zuur, Charlotte L., Shannon, Kerwin F., Seinstra, Beatrijs A., Rawson, Robert V., Haanen, John B. A. G., Ch'ng, Sydney, Naipal, Kishan A. T., Stretch, Jonathan, van Thienen, Johannes V., Rtshiladze, Michael A. ... Long, Georgina V. (2024). Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. New England Journal of Medicine. doi: 10.1056/NEJMoa2402604 |
|
2024 Journal Article The features and management of acquired resistance to PD1-based therapy in metastatic melanomaHepner, Adriana, Versluis, Judith M., Wallace, Roslyn, Allayous, Clara, Brown, Lauren Julia, Trojaniello, Claudia, Gerard, Camille Lea, Jansen, Yanina JL, Bhave, Prachi, Neyns, Bart, Haydon, Andrew, Michielin, Olivier, Mangana, Joanna, Klein, Oliver, Shoushtari, Alexander N., Warner, Allison Betof, Ascierto, Paolo Antonio, McQuade, Jennifer Leigh, Carlino, Matteo S., Zimmer, Lisa, Lebbe, Celeste, Johnson, Douglas B., Sandhu, Shahneen, Atkinson, Victoria, Blank, Christian U., Lo, Serigne N., Long, Georgina V. and Menzies, Alexander M. (2024). The features and management of acquired resistance to PD1-based therapy in metastatic melanoma. European Journal of Cancer, 196 113441. doi: 10.1016/j.ejca.2023.113441 |
|
2023 Journal Article The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimabMallardo, Domenico, Woodford, Rachel, Menzies, Alexander M., Zimmer, Lisa, Williamson, Andrew, Ramelyte, Egle, Dimitriou, Florentia, Wicky, Alexandre, Wallace, Roslyn, Mallardo, Mario, Cortellini, Alessio, Budillon, Alfredo, Atkinson, Victoria, Sandhu, Shahneen, Olivier, Michielin, Dummer, Reinhard, Lorigan, Paul, Schadendorf, Dirk, Long, Georgina V., Simeone, Ester and Ascierto, Paolo A. (2023). The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. Journal of Translational Medicine, 21 (1) 753. doi: 10.1186/s12967-023-04607-4 |
|
2023 Journal Article Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanomaGoodman, Rachel S., Di Guardo, Lorenza, Maurichi, Andrea, Kirwin, Brendan, Khattak, Adnan, Vanella, Vito, Lee, Joanna, Lawless, Aleigha, Czapla, Juliane, Spagnoletti, Andrea, Ambrosini, Margherita, Livingstone, Elisabeth, Long, Georgina V., Sullivan, Ryan J., Carlino, Matteo S., Atkinson, Victoria, Trojanello, Claudia, Ascierto, Paolo A., Schadendorf, Dirk, Warburton, Lydia, Menzies, Alexander M., Santinami, Mario and Johnson, Douglas B. (2023). Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma. European Journal of Cancer, 194 113354, 113354. doi: 10.1016/j.ejca.2023.113354 |
|
2023 Journal Article Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in CombinationArance, Ana, de la Cruz-Merino, Luis, Petrella, Teresa M., Jamal, Rahima, Ny, Lars, Carneiro, Ana, Berrocal, Alfonso, Márquez-Rodas, Ivan, Spreafico, Anna, Atkinson, Victoria, Costa Svedman, Fernanda, Mant, Andrew, Khattak, Muhammad A., Mihalcioiu, Catalin, Jang, Sekwon, Cowey, C Lance, Smith, Alan D., Hawk, Natalyn, Chen, Ke, Diede, Scott J., Krepler, Clemens and Long, Georgina V. (2023). Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. Journal of Clinical Oncology, 41 (1), 75-85. doi: 10.1200/JCO.22.00221 |
|
2023 Conference Publication Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trialKhattak, Adnan, Weber, Jeffrey S., Meniawy, Tarek, Taylor, Matthew H., Ansstas, George, Kim, Kevin B., McKean, Meredith, Long, Georgina V., Sullivan, Ryan J., Faries, Mark B., Tran, Thuy, Cowey, Charles Lance, Medina, Theresa Michelle, Segar, Jennifer Margaret, Atkinson, Victoria, Gibney, Geoffrey Thomas, Luke, Jason J., Buchbinder, Elizabeth Iannotti, Meehan, Robert S., Carlino, Matteo S. and on behalf of Moderna Author's Group (2023). Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Philadelphia, PA United States: Lippincott Williams & Wilkins. doi: 10.1200/JCO.2023.41.17_suppl.LBA9503 |
|
2023 Journal Article Health-related quality of life in patients with melanoma brain metastases treated with immunotherapyThompson, Jake R., Lai-Kwon, Julia, Morton, Rachael L., Guminski, Alexander D., Gonzalez, Maria, Atkinson, Victoria, Sandhu, Shahneen, Brown, Michael P., Menzies, Alexander M., Mcarthur, Grant A., Lo, Serigne N., Long, Georgina V. and Bartula, Iris (2023). Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy. Immunotherapy, 15 (8), 593-610. doi: 10.2217/imt-2022-0262 |
|
2023 Journal Article Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)Weber, Jeffrey S., Schadendorf, Dirk, Del Vecchio, Michele, Larkin, James, Atkinson, Victoria, Schenker, Michael, Pigozzo, Jacopo, Gogas, Helen, Dalle, Stéphane, Meyer, Nicolas, Ascierto, Paolo A., Sandhu, Shahneen, Eigentler, Thomas, Gutzmer, Ralf, Hassel, Jessica C., Robert, Caroline, Carlino, Matteo S., Di Giacomo, Anna Maria, Butler, Marcus O., Muñoz-Couselo, Eva, Brown, Michael P., Rutkowski, Piotr, Haydon, Andrew, Grob, Jean-Jacques, Schachter, Jacob, Queirolo, Paola, De La Cruz-Merino, Luis, Van Der Westhuizen, Andre, Menzies, Alexander M. ... Long, Georgina V. (2023). Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of Clinical Oncology, 41 (3), 517-527. doi: 10.1200/JCO.22.00533 |
|
2023 Journal Article Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapySandhu, Shahneen, Atkinson, Victoria, Cao, Maria González, Medina, Theresa, Rivas, Ainara Soria, Menzies, Alexander M., Caro, Ivor, Roberts, Louise, Song, Yuyao, Yan, Yibing, Guo, Yu, Xue, Cloris and Long, Georgina V. (2023). Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy. European Journal of Cancer, 178, 180-190. doi: 10.1016/j.ejca.2022.10.019 |
|
2023 Journal Article Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional surveyThompson, Jake R., Fu, Hong, Saw, Robyn P. M., Sherman, Kerry A., Beedle, Victoria, Atkinson, Victoria, Boyle, Frances, O’Sullivan, Niamh A., Martin, Linda K. and Bartula, Iris (2023). Supportive care needs in Australian melanoma patients and caregivers: results from a quantitative cross-sectional survey. Quality of Life Research, 32 (12), 3531-3545. doi: 10.1007/s11136-023-03492-0 |
|
2023 Journal Article BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomesLee, Joanna, Ahmed, Tasnia, Maurichi, Andrea, Di Guardo, Lorenzo, Stagno, Anna M., Warburton, Lydia, Taylor, Amelia. M., Livingstone, Elisabeth, Rehman, Saba, Khattak, Adnan, Kahler, Katharina C., Vanella, Vito, Atkinson, Victoria, Millward, Michael, Schadendorf, Dirk, Johnson, Douglas B., Ascierto, Paolo A., Hauschild, Axel, Lo, Serigne N., Long, Georgina V., Menzies, Alexander M. and Carlino, Matteo S. (2023). BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. European Journal of Cancer, 179, 87-97. doi: 10.1016/j.ejca.2022.11.009 |
|
2022 Journal Article Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaLarkin, James, Weber, Jeffrey, Del Vecchio, Michele, Gogas, Helen, Arance, Ana M., Dalle, Stephane, Cowey, C. Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Márquez-Rodas, Iván, Butler, Marcus O., Di Giacomo, Anna Marie, Middleton, Mark R., De la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew, Fecher, Leslie A., Millward, Michael, Khushalani, Nikhil I., Queirolo, Paola, Long, Georgina V., Lobo, Maurice, Askelson, Margarita, Ascierto, Paolo A. and Mandalá, Mario (2022). Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European Journal of Cancer, 173, 285-296. doi: 10.1016/j.ejca.2022.06.041 |
|
2022 Conference Publication Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinomaAoude, L.G., Bonazzi, V.F., Brosda, S., Wong, B., Moradi, H., Lonie, J., Bradford, J., Bloxham, C., Atkinson, V.G., Law, P., Lampe, G., Smithers, M., Waddell, N., Vegh, V., Miles, K. and Barbour, A.P. (2022). Radiomics biomarkers are associated with survival in patients with oesophageal adenocarcinoma. ESMO Congress 2022, Singapore, 9 - 13 September 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.07.1357 |
|
2022 Journal Article Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort studyDimitriou, F., Namikawa, K., Reijers, I. L.M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., Mehmi, I., Atkinson, V., Klein, O., Stonesifer, C. J., Zaman, F., Haydon, A., Carvajal, R. D., Hamid, O., Dummer, R., Hauschild, A. ... Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33 (9), 968-980. doi: 10.1016/j.annonc.2022.06.004 |
|
2022 Journal Article In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case seriesSanjida, Saira, Betz-Stablein, Brigid, Atkinson, Victoria, Janda, Monika, Barsoum, Ramez, Edwards, Harrison Aljian, Chiu, Frank, Tran, My Co, Soyer, H. Peter and Schaider, Helmut (2022). In-depth characterisation of real-world advanced melanoma patients receiving immunotherapies and/or targeted therapies: a case series. Cancers, 14 (11) 2801, 2801. doi: 10.3390/cancers14112801 |
|
2022 Conference Publication Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancerIqbal, Samreen, Atkinson, Victoria, Arneil, Melissa, Andelkovic, Vladimir and Roberts, Kate Elizabeth (2022). Outcomes of neoadjuvant and definitive CROSS (carboplatin and paclitaxel chemoradiotherapy) in oesophageal cancer. 2022 ASCO Annual Meeting, Chicago, IL United States, 3-7 June 2022. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2022.40.16_suppl.e16033 |
|
2022 Journal Article Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant TherapyNg, Gary, Xu, Wen and Atkinson, Victoria (2022). Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy. Current Oncology Reports, 24 (10), 1273-1280. doi: 10.1007/s11912-022-01288-y |
|
2022 Journal Article Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomesShanker, Mihir D., Garimall, Sidyarth, Gatt, Nick, Foley, Heath, Crowley, Samuel, Le Cornu, Emma, Muscat, Kendall, Soon, Wei, Atkinson, Victoria, Xu, Wen, Watkins, Trevor, Huo, Michael, Foote, Matthew C. and Pinkham, Mark B. (2022). Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of Medical Imaging and Radiation Oncology, 66 (4), 536-545. doi: 10.1111/1754-9485.13403 |
